William Mariner Greenman Cerus Corp (CERS) insider trading activity

William Mariner Greenman is President and CEO of CERUS CORP. Currently has a direct ownership of 4.31 Million shares of CERS, which is worth approximately $6.34 Million. The most recent transaction as insider was on Mar 07, 2025, when has been sold 60,984 shares (Common Stock) at a price of $1.5 per share, resulting in proceeds of $91,476. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 4.31M

35.47% 3M change

32.91% 12M change

Total Value Held $6.34 Million

William Mariner Greenman Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 07 2025	SELL Open market or private sale	$91,476 $1.5 p/Share	60,984 Reduced 1.4%	4,309,758 Common Stock
Mar 06 2025	BUY Grant, award, or other acquisition	-	1,140,742 Added 20.7%	4,370,742 Common Stock
Mar 04 2025	SELL Open market or private sale	$35,685 $1.55 p/Share	23,023 Reduced 0.71%	3,230,000 Common Stock
Mar 03 2025	BUY Exercise of conversion of derivative security	-	57,637 Added 1.74%	3,253,023 Common Stock
Mar 14 2024	SELL Open market or private sale	$128,494 $2.02 p/Share	63,611 Reduced 1.96%	3,181,281 Common Stock
Mar 13 2024	SELL Open market or private sale	$128,368 $2.06 p/Share	62,315 Reduced 1.88%	3,244,892 Common Stock
Mar 12 2024	BUY Exercise of conversion of derivative security	-	64,666 Added 1.92%	3,307,207 Common Stock
Mar 01 2024	BUY Grant, award, or other acquisition	-	575,000 Added 15.06%	3,242,541 Restricted Stock Unit
Mar 13 2023	SELL Open market or private sale	$169,344 $2.8 p/Share	60,480 Reduced 2.22%	2,658,346 Common Stock
Mar 12 2023	BUY Exercise of conversion of derivative security	-	172,192 Added 6.03%	2,681,078 Common Stock
Mar 01 2023	BUY Grant, award, or other acquisition	-	575,000 Added 18.42%	2,546,634 Restricted Stock Unit
Mar 14 2022	SELL Open market or private sale	$831,706 $5.04 p/Share	165,021 Reduced 7.74%	1,967,192 Common Stock
Mar 12 2022	BUY Exercise of conversion of derivative security	-	320,695 Added 13.82%	2,000,468 Common Stock
Mar 01 2022	BUY Grant, award, or other acquisition	-	217,500 Added 10.72%	1,811,518 Common Stock
Feb 25 2022	SELL Open market or private sale	$1,760,182 $5.71 p/Share	308,263 Reduced 16.2%	1,594,018 Common Stock
Feb 25 2022	BUY Exercise of conversion of derivative security	$1,425,000 $3.75 p/Share	380,000 Added 16.65%	1,902,281 Common Stock
Aug 03 2021	BUY Exercise of conversion of derivative security	$208,000 $2.08 p/Share	100,000 Added 6.18%	1,518,672 Common Stock
Apr 16 2021	SELL Payment of exercise price or tax liability	$1,485,005 $6.35 p/Share	233,859 Reduced 14.15%	1,418,672 Common Stock
Apr 16 2021	BUY Exercise of conversion of derivative security	$1,485,000 $2.7 p/Share	550,000 Added 24.97%	1,652,531 Common Stock
Mar 15 2021	SELL Open market or private sale	$997,877 $6.38 p/Share	156,407 Reduced 12.42%	1,102,531 Common Stock
Mar 12 2021	BUY Exercise of conversion of derivative security	-	327,696 Added 22.1%	1,155,015 Common Stock

Also insider at

KDNY

CHINOOK THERAPEUTICS, INC. Healthcare

Director

WMG